Skip to main content

Nuvectis Pharma, Inc.

NVCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001875558

No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Nuvectis Pharma, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of NVCT: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders4041+1
Shares1.56M1.21M−356.9K (−22.8%)
Value$12.8M$7.63M−$5.18M (−40.4%)

New holders (17)

Institutions that held Nuvectis Pharma, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to NVCT in Q2 2024
InstitutionSharesValue% of portfolio
Goldman Sachs Group Inc61,570$389.7K0.00%
Y-Intercept (Hong Kong) Ltd23,173$146.7K0.01%
Jane Street Group, LLC17,021$107.7K0.00%
Citadel Advisors LLC14,937$94.6K0.00%
HRT Financial LP13,627$86.0K0.00%
Centiva Capital, LP13,300$84.2K0.00%
Two Sigma Investments, LP13,044$82.6K0.00%
Baxter Bros Inc12,500$79.1K0.01%
Point72 Asia (Singapore) Pte. Ltd.9,203$58.3K0.01%
Qube Research & Technologies Ltd7,978$50.5K0.00%
Mirae Asset Global ETFs Holdings Ltd.3,254$20.6K0.00%
Point72 (DIFC) Ltd1,249$7.91K0.00%
Catalyst Funds Management Pty Ltd900$5.70K0.00%
Macquarie Group Ltd355$2.25K0.00%
Nisa Investment Advisors, LLC212$1.34K0.00%
Steward Partners Investment Advisory, LLC100$6330.00%
CWM, LLC16$00.00%

Sold out (16)

Institutions that held Nuvectis Pharma, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.